Skip to main content

Advertisement

Table 2 Treatment assignment and response assessment, B cell ALL (n = 196)

From: Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia

Variable Value Count %
Induction arma A 125 63.8
B 50 25.5
C 21 10.7
Day 15 BM morphology M1 182 92.9
M2 8 4.1
M3 5 2.6
Missing 1 0.5
Day 15 BM MRD (%) < 0.01 84 42.9
≥ 0.01 50 25.5
Not available 62 31.6
Day 29 BM morphology M1 191 97.4
M2 1 0.5
M3 2 1.0
Not available 2 1.0
Day 29 BM MRD (%) < 0.01 (negative) 177 90.3
≥ 0.01 (positive) 13 6.6
Not determined 6 3.1
Post induction armb A 114 58.2
B 38 19.4
C 40 20.4
Not applicable 4 2.0
  1. aPatients with Philadelphia translocation positive were excluded from the analysis (n = 4)
  2. b4 patients were not eligible for post-induction analysis and were reported as “Not applicable”. Post-induction Arms C and C + HDMTX were combined